Evaluation of Anti-Arthritis Activity of Topical Oxaprozin Nanogel on Animal Model

Osteoarthritis (OA) is defined by the progressive and irreversible deterioration of articular cartilage accompanied by a subsequent inflammatory response. Nonetheless, most medicinal medications for osteoarthritis only mitigate symptoms without targeting the underlying disease. We engineered an inflammationresponsive carrier and encapsulated bioactive substances to address this issue. Oxaprozin is a non-steroidal antiinflammatory agent characterised by insufficient oral bioavailability and gastrointestinal adverse effects. This project aims to develop a unique topical Oxaprozin nanogel. Arthritis was produced in Wistar rats utilising Freund's complete adjuvant (FCA), and the formulation's antiarthritic efficacy was examined. The effects were juxtaposed with those of Diclofenac. Upon the study's conclusion, blood samples were collected for biochemical as well as haematological analysis. The Oxaprozin Nanogel formulation demonstrated considerable antiarthritic efficacy, comparable to that of Diclofenac. The formulation's antiarthritic efficacy is corroborated by biochemical and haematological analyses. The oxaprozin nanogel formulation demonstrated considerable antiarthritic efficacy against FCA-induced arthritis in Wistar rats.